The efficacy of early administration of dual antiplatelet
therapy (
DAPT) for
secondary prevention after
acute ischemic stroke or
transient ischemic attack (TIA) is uncertain. This systematic review and meta-analysis compares the safety and efficacy of early administration (<24 hours) of
DAPT (using either
clopidogrel or
ticagrelor with
aspirin) versus single antiplatelet
therapy (SAPT;
aspirin alone) in acute non-cardioembolic
ischemic stroke or TIA, incorporating data from large randomized controlled trials. Published trials fulfilling our criteria were identified from an electronic search of MEDLINE, with key words including: "
clopidogrel or
ticagrelor", "
aspirin", "
ischemic stroke", "
transient ischemic attack", and "randomized controlled trial". Included were 3 randomized controlled trials of 21,067 patients assessing early administration (<24 hours from symptom onset) of
DAPT versus SAPT in non-cardioembolic
acute ischemic stroke or TIA. Our efficacy outcomes were
ischemic stroke and all-cause mortality. Our safety outcome was severe
bleeding. We performed a meta-analysis to pool results with a hierarchical Bayesian random-effects model. Dual antiplatelet
therapy significantly reduced the risk of
ischemic stroke (hazard ratio [HR], 0.73; 95% credible interval [CrI]: 0.54, 0.97), while increasing the risk of severe
bleeding (HR, 2.48; 95% CrI: 1.07, 5.26). There was a non-significant numerical trend toward increased mortality with
DAPT (HR, 1.29; 95% CrI: 0.73, 2.23). These observations were robust under the sensitivity analysis. In the present systematic review and meta-analysis of randomized controlled trials,
DAPT reduced the risk of
ischemic stroke at the cost of an increase in severe
bleeding. Additional trials examining the ideal timing of
DAPT administration are needed to thoroughly investigate the role, if any, of routine
DAPT in patients with non-cardioembolic
ischemic stroke or high-risk TIA.